American Society of Hirudotherapy

Decorsin

RGD-containing peptide that inhibits the platelet GP IIb/IIIa receptor; the drug eptifibatide was modelled on snake-venom barbourin, not on decorsin.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 26, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • Decorsin4.4 kDa
Molecular weight (kilodaltons) of Decorsin (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Clinical and regulatory evidence (FDA-approved derived drug)
Evidence level
In vitro
Drug vs leech
Purified natural compound
Safety domains
Bleeding

Clinical translation limit

Decorsin itself is NOT an FDA-approved drug. The synthetic GP IIb/IIIa antagonist eptifibatide was designed from the KGD sequence of the snake-venom disintegrin barbourin (Scarborough 1991, 1993), not from decorsin; the two share a target, not an origin. Decorsin's preclinical mechanism does NOT establish clinical efficacy of whole-leech therapy.

A bundle of overlaid green ribbon models of one small protein, showing the same fold in each model with flexible ends fanning out.
Decorsin, an RGD protein from leech saliva that affects blood clotting: the overlaid models of its solution NMR structure (PDB 1DEC). Source: PDBe, EMBL-EBI — PDB 1DEC · PDBe public data (public domain)

Molecular Profile

Category
Antiplatelet
Evidence tier
Tier A — FDA-approved derivative
Molecular weight
4,400 Da
Source species
Macrobdella decora (North American leech)
Discovered
1990 · Seymour et al.

Biological Targets

  • → platelet integrin αIIbβ3 (GP IIb/IIIa)

Key Citations

  1. Seymour JL et al. (1990), J Biol Chem

External Resources

    Related Antiplatelet Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.